DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
HOLX logo

Hologic, Inc. Stock Price

NasdaqGS:HOLX Community·US$16.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

HOLX Share Price Performance

US$76.01
10.51 (16.04%)
​
US$76.67
Fair Value
US$76.01
10.51 (16.04%)
Fairly Valued intrinsic discount
US$76.67
Fair Value
Price US$76.01
AnalystConsensusTarget US$76.67
Fri, 10 Apr 26
Fair ValueUS$76.67
Share Pricen/a

HOLX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$76.67 Fairly Valued intrinsic discount

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
HOLX logo
Hologic
Fairly Valued intrinsic discount

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 10 Apr
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
HOLX logo

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Fair Value: US$76.67 Fairly Valued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

1 Risk
2 Rewards
View Full Analysis

Hologic, Inc. Key Details

US$4.1b

Revenue

US$1.6b

Cost of Revenue

US$2.5b

Gross Profit

US$1.9b

Other Expenses

US$543.8m

Earnings

Last Reported Earnings
Dec 27, 2025
Next Reporting Earnings
n/a
2.44
60.38%
13.18%
47.8%
View Full Analysis

About HOLX

Founded
1985
Employees
7070
CEO
Stephen MacMillan
WebsiteView website
www.hologic.com

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Recent HOLX News & Updates

User avatar
Narrative Update • Apr 10

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.

Recent updates

No updates

Hologic, Inc. Competitors

ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$123.7b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.9b
MDT logo

Medtronic

Symbol: NYSE:MDT
Market cap: US$118.2b
SYK logo

Stryker

Symbol: NYSE:SYK
Market cap: US$106.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide